DBV TECHNOLOGIES SA (DBV.PA) Stock Price & Overview
EPA:DBV • FR0010417345
Current stock price
The current stock price of DBV.PA is 3.47 EUR. Today DBV.PA is down by -0.97%. In the past month the price decreased by -9.81%. In the past year, price increased by 190.55%.
DBV.PA Key Statistics
- Market Cap
- 965.875M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.65
- Dividend Yield
- N/A
DBV.PA Stock Performance
DBV.PA Stock Chart
DBV.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DBV.PA. When comparing the yearly performance of all stocks, DBV.PA is one of the better performing stocks in the market, outperforming 98.54% of all stocks.
DBV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA. The financial health of DBV.PA is average, but there are quite some concerns on its profitability.
DBV.PA Earnings
On March 26, 2026 DBV.PA reported an EPS of -0.23 and a revenue of 645.00K. The company missed EPS expectations (-107.02% surprise) and beat revenue expectations (4.35% surprise).
DBV.PA Forecast & Estimates
8 analysts have analysed DBV.PA and the average price target is 5.32 EUR. This implies a price increase of 53.37% is expected in the next year compared to the current price of 3.47.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBV.PA
DBV.PA Groups
Sector & Classification
DBV.PA Financial Highlights
Over the last trailing twelve months DBV.PA reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.05% | ||
| ROE | -87.19% | ||
| Debt/Equity | 0.03 |
DBV.PA Ownership
DBV.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 29.45 | 42.202B | ||
| 1AE | ARGENX SE | 29.42 | 42.19B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.117B | ||
| ABVX | ABIVAX SA | N/A | 8.555B | ||
| 2X1 | ABIVAX SA | N/A | 8.555B | ||
| GLPG | GALAPAGOS NV | N/A | 1.608B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.238B | ||
| PHARM | PHARMING GROUP NV | 48.59 | 1.036B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| PHGN | PHARMING GROUP NV | 45.96 | 975.297M | ||
| IVA | INVENTIVA SA | N/A | 939.888M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About DBV.PA
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
IPO: 2012-03-29
DBV TECHNOLOGIES SA
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES FR
Employees: 117
Phone: 33155427878
DBV TECHNOLOGIES SA / DBV.PA FAQ
What does DBV do?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is the current price of DBV stock?
The current stock price of DBV.PA is 3.47 EUR. The price decreased by -0.97% in the last trading session.
Does DBV TECHNOLOGIES SA pay dividends?
DBV.PA does not pay a dividend.
How is the ChartMill rating for DBV TECHNOLOGIES SA?
DBV.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DBV stock to perform?
8 analysts have analysed DBV.PA and the average price target is 5.32 EUR. This implies a price increase of 53.37% is expected in the next year compared to the current price of 3.47.
Who owns DBV TECHNOLOGIES SA?
You can find the ownership structure of DBV TECHNOLOGIES SA (DBV.PA) on the Ownership tab.